Morgan Stanley Catalyst Biosciences, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$0.33 - $0.65 $7,143 - $14,070	21,647 Added 28.45%	97,745 $46,000
Q2 2023 Aug 14, 2023	BUY	$0.2 - $0.35 $7,538 - $13,192	37,694 Added 98.15%	76,098 $26,000
Q1 2023 May 15, 2023	BUY	$0.19 - $0.64 $455 - $1,532	2,395 Added 6.65%	38,404 $8,000
Q4 2022 Feb 14, 2023	SELL	$0.49 - $0.57 $48 - $55	-98 Reduced 0.27%	36,009 $19,000
Q3 2022 Nov 14, 2022	SELL	$0.49 - $1.95 $219 - $873	-448 Reduced 1.23%	36,107 $18,000
Q2 2022 Oct 27, 2022	SELL	$0.36 - $1.78 $9,421 - $46,582	-26,170 Reduced 41.72%	36,555 $65,000
Q2 2022 Aug 15, 2022	SELL	$0.36 - $1.78 $9,421 - $46,582	-26,170 Reduced 41.72%	36,555 $65,000
Q1 2022 Oct 27, 2022	BUY	$0.51 - $1.0 $13,346 - $26,170	26,170 Added 71.59%	62,725 $41,000
Q1 2022 May 13, 2022	SELL	$0.51 - $1.0 $230,266 - $451,503	-451,503 Reduced 87.8%	62,725 $41,000
Q4 2021 Feb 14, 2022	BUY	$0.91 - $4.16 $396,894 - $1.81 Million	436,148 Added 558.59%	514,228 $470,000
Q3 2021 Nov 15, 2021	BUY	$3.78 - $5.18 $295,142 - $404,454	78,080 New	78,080 $321,000

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.